15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Lexicon Pharmaceuticals Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $3.10 to $6.00, a moderate spread. The average target of $4.55 sits 95% above the current $2.33. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.06 next quarter toward $-0.21 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Lexicon Pharmaceuticals Inc.
As of Jul, 2 of 2 firms rate LXRX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
LXRX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.06
Range $-0.07 – $-0.05 · 5 analysts · +49% YoY
Next period, 5 analysts expect Lexicon Pharmaceuticals Inc to earn $-0.06 a share (range $-0.07 – $-0.05), versus $-0.04 a year earlier. Full-year consensus is $-0.16, growing to $-0.21 the year after.
REVENUE · NEXT QUARTER
$3.1M
Range $0 – $11.2M · 5 analysts · -78% YoY
Revenue is expected to reach $3.1M (range $0 – $11.2M), -78.3% year-over-year. Full-year consensus is $38.2M, rising to $20.2M next year.
Top analysts covering Lexicon Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LXRX.
#1
Yigal Nochomovitz
Citigroup · Rank #131
Buy
$3.10+32.8% to target
Overall win rate
43%
+ Follow
#2
Yasmeen Rahimi
Piper Sandler · Rank #152
Buy
$6.00+157.0% to target
Overall win rate
34%
+ Follow
#3
Joseph Stringer
Needham · Rank #168
Hold
No targeton LXRX
Overall win rate
36%
+ Follow
#4
Joseph Pantginis
HC Wainwright & Co. · Rank #266
Buy
$6.00+157.0% to target
Overall win rate
32%
+ Follow
#5
Andrew Tsai
Jefferies
Hold
$0.85-63.6% to target
Coverage
—
+ Follow
LXRX stock forecast FAQ
What is LXRX's average 12-month price target?+
The 2 analysts with a live target average $4.55 for Lexicon Pharmaceuticals Inc over the next 12 months, ranging from a $6.00 high to a $3.10 low.
Is LXRX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for LXRX?+
The Street-high target is $6.00 (HC Wainwright & Co.), and the Street-low is $3.10 (Citigroup). The average of all 2 active targets is $4.55.
How many Wall Street analysts cover LXRX?+
2 analysts have an active rating on Lexicon Pharmaceuticals Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering LXRX?+
Among analysts who currently cover LXRX, Yigal Nochomovitz of Citigroup has the strongest overall Quantellect track record (Rank #131). Their current call is Buy with a $3.10 target.
What is Lexicon Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.06 per share (range $-0.07 – $-0.05) across 5 analysts. Full-year EPS is projected at $-0.16, rising to $-0.21 the following year.
How much revenue is Lexicon Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $3.1M (range $0 – $11.2M). Full-year revenue is projected at $38.2M, growing to $20.2M next year.
Have analysts been upgrading or downgrading LXRX lately?+
As of Jul, 2 of 2 firms rate LXRX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LXRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
